Thomas Helland
Biochemistry, Genetics and Molecular Biology · University of Michigan
Publications
35
Citations
363
Est. group size
~1
Recurring co-author estimate
Active years
13
Publishing since 2013
Typically publishes in teams of ~14 · 7% small-team papers (≤3 authors) · across 21 venues
- Monitoring of circulating tumor <scp>DNA</scp> allows early detection of disease relapse in patients with operable breast cancer
Molecular Oncology · 2025
- Author response for "Monitoring of circulating tumor DNA allows early detection of disease relapse in patients with operable breast cancer"
2025
- Nonlinear Mixed‐Effects Model of Z‐Endoxifen Concentrations in Tamoxifen‐Treated Patients from the CEPAM Cohort
Clinical Pharmacology & Therapeutics · 2024
- Quantitative proteomics reveals serum proteome alterations during metastatic disease progression in breast cancer patients
Clinical Proteomics · 2024
- A randomized Phase I pre-operative window trial of transdermal endoxifen in women planning mastectomy: Evaluation of dermal safety, intra-mammary drug distribution, and biologic effects
Biomedicine & Pharmacotherapy · 2024
- Abstract RF01-02: A randomized Phase I pre-operative window trial of transdermal endoxifen in women planning mastectomy: evaluation of dermal safety, intra-mammary drug distribution, and biologic effects
Cancer Research · 2024
- Håvard Søiland
Tidsskrift for Den norske legeforening · 2024
- Importance of endocrine treatment adherence and persistence in breast cancer survivorship: a systematic review
BMC Cancer · 2023
- Presurgical Oral Tamoxifen vs Transdermal 4-Hydroxytamoxifen in Women With Ductal Carcinoma In Situ
JAMA Surgery · 2023
- Abstract PD15-12: PD15-12 A pre-surgical window trial of oral tamoxifen versus transdermal 4-hydroxytamoxifen gel in women with estrogen receptor positive duct carcinoma in situ (DCIS)
Cancer Research · 2023
- Liquid biopsies and patient-reported outcome measures for integrative monitoring of patients with early-stage breast cancer: a study protocol for the longitudinal observational Prospective Breast Cancer Biobanking (PBCB) study
BMJ Open · 2022
- Generating a Precision Endoxifen Prediction Algorithm to Advance Personalized Tamoxifen Treatment in Patients with Breast Cancer
Journal of Personalized Medicine · 2021
- Association of CYP2D6 genotype and tamoxifen metabolites with breast cancer recurrence in a low-dose trial
npj Breast Cancer · 2021
- Simultaneous Quantification of Aromatase Inhibitors and Estrogens in Postmenopausal Breast Cancer Patients
The Journal of Clinical Endocrinology & Metabolism · 2021
- Effect of Genetic Variability in 20 Pharmacogenes on Concentrations of Tamoxifen and Its Metabolites
Journal of Personalized Medicine · 2021
- Cancer Research×5
- Journal of Personalized Medicine×2
- Molecular Oncology×2
- BMC Cancer×1
- Breast Cancer Research×1
- James M. Rae
Biochemistry, Genetics and Molecular Biology · University of Michigan
- Todd C. Skaar
Biochemistry, Genetics and Molecular Biology · Indiana University
- Santosh Philips
Biochemistry, Genetics and Molecular Biology · Indiana University
- Elyse M. Petrunak
Biochemistry, Genetics and Molecular Biology · University of Michigan
- N. Lynn Henry
Biochemistry, Genetics and Molecular Biology · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile